Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SCIDEV LTD Interim / Quarterly Report 2017

Aug 24, 2017

65761_rns_2017-08-24_21aad72f-cbc6-4724-bc2e-bd2f13e2adf1.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

Suite 105 48 Atchison Street St Leonards NSW 2065 Australia

Phone: +61 (0) 438 675 510 Email: [email protected] Website: www.scidev.com.au ASX code : SDV

SciDev Ltd

(Formerly known as Intec Ltd)

Appendix 4E - Preliminary Final Report - 30 June 2017

SciDev Ltd Appendix 4E Preliminary final report

1. Company details

Name of entity: SciDev Ltd
ABN: 25 001 150 849
Reporting period: For the year ended 30 June 2017
Previous period: For the year ended 30 June 2016

2. Results for announcement to the market

$
Revenues from ordinary activities up 35.3%to 1,925,233
Loss from ordinary activities after tax attributable to the owners of SciDevLtd up 41.9%to (682,151)
Loss for the year attributable to the owners of SciDev Limited up 41.9%to (682,151)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Brief Explanation of any of the figures reported above

The Company and controlled entities (the Group) generated an operating loss after income tax of $597,340 (30 June 2016: $458,130) and net cash outflows from operations of $225,298 ($541,397 in the year ended 30 June 2016). At 30 June 2017, the consolidated entity had net assets of $2,461,700 (2016: $1,766,899) and cash balances of $938,714 (2016: $479,089).

This Appendix 4E should be read in conjunction with the Half-Year Financial Report of the Group as at 31 December 2016 and the Annual Financial Report of SciDev, due to be released in September 2017, for the year ended 30 June 2017. It is also recommended that the Appendix 4E be considered together with any public announcements made by the Group since commencement of the 2016/17 financial year on 1 July 2016 in accordance with the continuous disclosure obligations arising under the Corporations Act, 2001.

Events Occurring after Balance Date

On 14 August 2017, the Company issued 6.5 million unquoted options to executive and staff (not Directors). The options were granted under the SciDev Ltd Employee Share Scheme. The options have an exercise price of $0.025 and an expiry date of 28 November 2019.

No matter or circumstance has arisen since 30 June 2017 that has significantly affected or may significantly affect the consolidated entities operations, the results of these operations, or the consolidated entities state of affairs in future financial years.

Net tangible assets

ReportingperiodCents PreviousperiodCents
Net tangible assets per ordinary security 0.24 0.17

3. Control gained over entities

Not applicable.

4. Loss of control over entities

Not applicable.

5. Dividends

Current period There were no dividends paid, recommended or declared during the current financial period.

SciDev Ltd Appendix 4E Preliminary final report

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

6. Dividend reinvestment plans

Not applicable.

7. Details of associates and joint ventureentities

Not applicable.

8. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

9. Audit statement

This report is based on accounts that are in the process of being audited.

10. Attachments

The condensed financial statements of SciDev Ltd for the year ended 30 June 2017 is attached.

11. Signed

Signed Date: 25 August 2017

Kieran G Rodgers Managing Director Sydney

SciDev Ltd Condensed consolidated statement of profit or loss and other comprehensive income For the year ended 30 June 2017

Note 2017$ 2016$
Revenue 1,925,233 1,423,072
Other income 243,802 351,138
Expenses
Changes in inventories (46,673) 22,263
Raw materials and consumables used (955,068) (780,694)
Employee benefits expense (741,253) (701,317)
Depreciation and amortisation expense (152,193) (85,763)
Engineering and other consultants expenses (157,684) (147,660)
Insurance (44,081) (37,247)
Listing and share registry expenses (38,635) (25,496)
Professional fees (140,974) (106,167)
Rent and related expenses (124,467) (105,137)
Travel, accommodation and conference (90,162) (71,740)
Other expenses (125,012) (81,994)
Finance costs (26,628) (26,427)
Loss before income tax expense (473,795) (373,169)
Income tax expense (123,545) (84,961)
Loss after income tax expense for the year (597,340) (458,130)
Other comprehensive income
Items that may be reclassified subsequently to profit or loss
Gain on revaluation of other financial assets - 22,465
Reclassification on disposal of available-for-sale financial assets - (40,565)
Other comprehensive income for the year, net of tax - (18,100)
Total comprehensive income for the year (597,340) (476,230)
Loss for the year is attributable to:
Non-controlling interest 84,811 22,458
Owners of SciDev Ltd (682,151) (480,588)
(597,340) (458,130)
Total comprehensive income for the year is attributable to:
Non-controlling interest 84,811 22,458
Owners of SciDev Limited (682,151) (498,688)
(597,340) (476,230)
Cents Cents
Basic earnings per share 11 (0.18) (0.16)
Diluted earnings per share 11 (0.18) (0.16)

Refer to note 2 for detailed information on Restatement of comparatives.

The above condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

SciDev Ltd Condensed consolidated statement of financial position As at 30 June 2017

Note 2017$ 2016$ 1 July 2015$
Assets
Current assets
Cash and cash equivalents 5 938,714 478,089 926,394
Trade and other receivables 334,017 215,524 320,569
Inventories 231,839 278,040 255,777
Income tax refund due - 11,253 5,425
Other 1,754 1,756 537
Total current assets 1,506,324 984,662 1,508,702
Non-current assets
Other financial assets 2,900 2,900 -
Property, plant and equipment 291,201 228,545 221,323
Intangibles 6 1,279,803 1,269,090 1,288,905
Other - - 57,200
Total non-current assets 1,573,904 1,500,535 1,567,428
Total assets 3,080,228 2,485,197 3,076,130
Liabilities
Current liabilities
Trade and other payables 358,410 105,136 177,754
Borrowings 11,957 336,491 355,466
Employee benefits 163,365 139,466 -
Provisions - - 111,298
Total current liabilities 533,732 581,093 644,518
Non-current liabilities
Borrowings 7 32,546 71,323 113,718
Deferred tax 52,250 65,882 74,765
Total non-current liabilities 84,796 137,205 188,483
Total liabilities 618,528 718,298 833,001
Net assets 2,461,700 1,766,899 2,243,129
EquityIssued capital 8 73,834,118 71,641,977 71,641,977
Reserves 2,008,395 2,653,594 2,671,694
Accumulated losses (73,380,813) (72,698,662) (72,218,074)
Equity attributable to the owners of SciDev Ltd 2,461,700 1,596,909 2,095,597
Non-controlling interest - 169,990 147,532
Total equity 2,461,700 1,766,899 2,243,129

Refer to note 2 for detailed information on Restatement of comparatives.

The above condensed consolidated statement of financial position should be read in conjunction with the accompanying

SciDev Ltd Condensed consolidated statement of changes in equity For the year ended 30 June 2017

Issuedcapital$ Reserves$ Accumulatedlosses$ Noncontrollinginterest$ Total equity$
Balance at 1 July 2015 71,641,977 2,671,694 (72,218,074) 147,532 2,243,129
Profit/(loss) after income tax expense for theyearOther comprehensive income for the year, net - - (480,588) 22,458 (458,130)
of tax - (18,100) - - (18,100)
Total comprehensive income for the year - (18,100) (480,588) 22,458 (476,230)
Balance at 30 June 2016 71,641,977 2,653,594 (72,698,662) 169,990 1,766,899
Issuedcapital$ Reserves$ Accumulatedlosses$ Noncontrollinginterest$ Total equity$
Balance at 1 July 2016 71,641,977 2,653,594 (72,698,662) 169,990 1,766,899
Profit/(loss) after income tax expense for theyearOther comprehensive income for the year, netof tax -- -- (682,151)- 84,811- (597,340)-
Total comprehensive income for the year - - (682,151) 84,811 (597,340)
Transactions with owners in their capacity asowners:
Contributions of equity, net of transaction costs(note 8)Transactions with non-controlling interests 2,192,141- -(645,199) -- -(254,801) 2,192,141(900,000)
Balance at 30 June 2017 73,834,118 2,008,395 (73,380,813) - 2,461,700

SciDev Ltd Condensed consolidated statement of cash flows For the year ended 30 June 2017

Note 2017$ 2016$
Cash flows from operating activitiesReceipts from customers (inclusive of GST)Payments to suppliers and employees (inclusive of GST) 1,999,539(2,304,164) 1,671,695(2,268,673)
Interest receivedR&D tax offset receivedInterest and other finance costs paidIncome taxes paid (304,625)13,387218,492(26,628)(125,924) (596,978)18,990162,690(26,427)(99,672)
Net cash used in operating activities (225,298) (541,397)
Cash flows from investing activitiesPayments for non-controlling interest in subsidiaryPayments for property, plant and equipmentPayments for intangiblesProceeds from disposal of property, plant and equipmentProceeds from disposal of intangibles 106 (660,000)(190,764)(52,143)-- -(58,414)-207,531(14,756)
Net cash from/(used in) investing activities (902,907) 134,361
Cash flows from financing activitiesProceeds from issue of sharesShare issue transaction costsRepayment of borrowings 88 2,100,000(147,859)(363,311) --(41,269)
Net cash from/(used in) financing activities 1,588,830 (41,269)
Net increase/(decrease) in cash and cash equivalentsCash and cash equivalents at the beginning of the financial year 460,625478,089 (448,305)926,394
Cash and cash equivalents at the end of the financial year 5 938,714 478,089

Note 1. Statement of significant accounting policies

Statement of compliance

This preliminary final report (the Report) is to be read in conjunction with any public announcements made by SciDev Ltd during the reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 and Australian Securities Exchange Listing Rules.

The preliminary final report has been prepared in accordance with Australian Accounting Standards (AASBs) adopted by the Australian Accounting Standards Board and the Corporations Act 2001.

The Report is presented in Australian dollars, which is the functional currency of SciDev Ltd and its controlled entities and has been prepared on the basis of historical cost except in accordance with relevant accounting policies where assets and liabilities are stated at their fair values.

Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are consistent with those of the previous financial year.

Comparatives

Where necessary, comparative figures have been adjusted to comply with the changes in presentation in the current period.

Going concern

The consolidated entity generated an operating loss after income tax of $597,340 (2016: $458,130) and net cash outflows from operations of $225,298 (2016: $541,397) in the year ended 30 June 2017. At 30 June 2017, the consolidated entity had net assets of $2,461,700 (2016: $1,766,899) and cash balances of $938,714 (2016: $479,089).

These matters give rise to a material uncertainty that may cast doubt whether the consolidated entity can continue as a going concern and realise its assets and extinguish its liabilities in the ordinary course of business and at amounts stated in the financial statements. The continuing viability of the consolidated entity and its ability to continue as a going concern and meet its debts and commitments as and when they fall due are dependent upon the consolidated entity being successful in the following:

  • Commercialisation of the Optiflox® System with resultant increased product sales and technology leasing fees;
  • The raising sufficient capital by way of either additional debt and/or equity capital; and
  • The receipt of proceeds from the sale of non-core assets.

The Directors are of the opinion that sufficient additional funding will be secured and are themselves likely to participate in any future equity capital raising. The financial report has therefore been prepared on the basis of a going concern. This basis presumes that funds from the above sources will be available to finance future operations, and to repay liabilities and that the realisation of assets and settlement of liabilities will occur in the normal course of business.

However, the Directors note that if sufficient funds are not raised through the above-mentioned sources, the going concern basis may not be appropriate with the result that the group may have to realise its assets and extinguish its liabilities other than in the ordinary course of business and in amounts different from those stated in the financial report.

Note 2. Restatement of comparatives

Reclassification

For the year ended 30 June 2016 the net gain on disposal of investments, income from subsidies and grants, and income from the reimbursement of expenses have been reclassified from 'Revenue' to 'Other income' in the statement of profit or loss.

The expenses in the statement of profit or loss for the year ended 30 June 2016 were not presented using a consistent classification based on either the nature of expenses or their function within the consolidated entity. For the year ended 30 June 2017 the consolidated entity has presented expenses in the statement of profit or loss based on the nature of the expense and the comparatives have been reclassified to reflect the changes in presentation.

The 30 June 2016 statement of financial position has been restated as follows: the income tax receivable and prepayments are disclosed separately on the face of the statement of financial position under current assets, and the loans from related related parties have been reclassified from trade and other payables to borrowings.

Note 2. Restatement of comparatives (continued)

Statement of profit or loss and other comprehensive income

Extract 2016$Reported $Adjustment 2016$Restated
Revenue 1,774,210 (351,138) 1,423,072
Other income - 351,138 351,138
ExpensesChanges in inventoriesRaw materials and consumables usedAdministration expenseInsuranceListing and share registry expensesProfessional feesTravel, accommodation and conferenceOther expenses -(758,431)(307,529)----(15,115) 22,263(22,263)307,529(37,247)(25,496)(106,167)(71,740)(66,879) 22,263(780,694)-(37,247)(25,496)(106,167)(71,740)(81,994)
Loss before income tax expense (373,169) - (373,169)
Income tax expense (84,961) - (84,961)
Loss after income tax expense for the year (458,130) - (458,130)
Other comprehensive income for the year, net of tax (18,100) - (18,100)
Total comprehensive income for the year (476,230) - (476,230)
Loss for the year is attributable to:Non-controlling interestOwners of SciDev Ltd 22,458(480,588) -- 22,458(480,588)
(458,130) - (458,130)
Total comprehensive income for the year is attributable to:Non-controlling interestOwners of SciDev Ltd 22,458(498,688)(476,230) --- 22,458(498,688)(476,230)

Note 2. Restatement of comparatives (continued)

Statement of financial position at the beginning of the earliest comparative period

1 July 2015$ $ 1 July 2015$
Extract Reported Adjustment Restated
Assets
Current assetsTrade and other receivablesIncome tax refund dueOther 326,531-- (5,962)5,425537 320,5695,425537
Total current assets 1,508,702 - 1,508,702
Total assets 3,076,130 - 3,076,130
Liabilities
Current liabilitiesTrade and other payablesBorrowingsTotal current liabilities 277,754255,466644,518 (100,000)100,000- 177,754355,466644,518
Total liabilities 833,001 - 833,001
Net assets 2,243,129 - 2,243,129

Statement of financial position at the end of the earliest comparative period

2016$ $ 2016$
Extract Reported Adjustment Restated
Assets
Current assetsTrade and other receivables 228,533 (13,009) 215,524
Income tax refund dueOther -- 11,2531,756 11,2531,756
Total current assets 984,662 - 984,662
Total assets 2,485,197 - 2,485,197
Liabilities
Current liabilities
Trade and other payablesBorrowings 205,136236,491 (100,000)100,000 105,136336,491
Total current liabilities 581,093 - 581,093
Total liabilities 718,298 - 718,298
Net assets 1,766,899 - 1,766,899

Note 3. Operating segments

Identification of reportable operating segments

The consolidated entity operates in primarily one geographical segment, namely Australia. The primary business segment is the treatment of industrial waste including the manufacture and supply of chemicals for the treatment of waste water.

Operating and business segments are reported in a manner consistent with the internal reporting provided to the chief operating decision makers. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors.

Note 4. Expenses

Significant movements (increases) in expenses during the reporting period related primarily to organic business growth, with the exception of Listing and Share registry fees and Professional Fees, where increases related primarily to capital raisings.

Note 5. Current assets - cash and cash equivalents

2017$ 2016$
Cash on handCash at bank 150438,564 150477,939
Cash on deposit 500,000 -
938,714 478,089

Note 6. Non-current assets - intangibles

2017$ 2016$
Goodwill - at cost 1,030,018 1,030,018
Trademarks and intellectual property - at costLess: Accumulated amortisation 374,833(125,048)249,785 322,690(83,618)239,072
1,279,803 1,269,090

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Goodwill$ Trademarksandintellectualproperty$ Total$
Balance at 1 July 2015 1,030,018 258,887 1,288,905
Additions - 14,756 14,756
Amortisation expense - (34,571) (34,571)
Balance at 30 June 2016 1,030,018 239,072 1,269,090
Additions - 52,143 52,143
Amortisation expense - (41,430) (41,430)
Balance at 30 June 2017 1,030,018 249,785 1,279,803

Note 6. Non-current assets - intangibles (continued)

Impairment testing

Goodwill which was acquired through a business combination, has been allocated to the Science Development Pty Ltd cash-generating unit (CGU). The recoverable amount of the consolidated entity's goodwill has been determined by a valuein-use calculation using a discounted cash flow model, based on a 1-year projection period approved by management and extrapolated for a further 4 years using variable rates, together with a terminal value.

Key assumptions are those to which the recoverable amount of an asset or cash-generating units is most sensitive.

Key assumptions in the discounted cashflow model include:

a. Post-tax discount rate of 12.5% (2016: 8%) per annum;

b. Revenue growth of 49% in 2018, 9% in 2019 and 16% in 2020 (2016: 93% in 2017, 66% in 2018 reducing to 4% in 2019);

c. Growth in gross margin of 56% in 2018, 9% in 2019 and 14% in 2020 (2016: 103% in 2017, 76% in 2018 reducing to 5% in 2019); and

d. Average per annum increase in operating expenses of 5% (2016: 18%).

The discount rate of 12.5% post-tax reflects management's estimate of the time value of money and the consolidated entity's weighted average cost of capital, the risk-free rate and the volatility of the share price relative to market movements.

Management believes the projected revenue growth rate is prudent and justified, based on past performance and management's expectations of market development.

The budgeted gross margin is based on past performance and management's expectations for the future.

Management has budgeted for operating costs based on the current structure of the business, but not reflecting any future restructurings or cost saving measures.

Sensitivity to change of assumptions

If the next year's financial budget used in the value-in-use calculation had been 10% lower than management's estimates at 30 June 2017, the consolidated entity would have a recoverable amount in excess of $2.02 million against the carrying amount of the cash generating unit to which the goodwill relates. If the post-tax discount rate applied to the cash flow projections of this CGU had been 20% higher than management's estimates (15% instead of 12.5%), the consolidated entity would have a recoverable amount in excess of $2.14 million against the carrying amount of intangible assets and property, plant and equipment.

Note 7. Non-current liabilities - borrowings

Financing arrangements

Unrestricted access was available at the reporting date to the following lines of credit:

2017$ 2016$
Total facilitiesTrade finance - 250,000
Used at the reporting dateTrade finance - 196,535
Unused at the reporting dateTrade finance - 53,465
Note 8. Equity - issued capital
2017Shares 2016Shares 2017$ 2016$
Ordinary shares - fully paid 494,818,673 299,818,669 73,834,118 71,641,977

Note 8. Equity - issued capital (continued)

Movements in ordinary share capital

Details Date Shares Issue price $
Balance 1 July 2015 299,818,669 71,641,977
BalanceShare placementShare purchase planShare placementAcquisition of shares in Science Developments PtyLtdShare issue transaction costs 30 June 201619 December 201612 January 20172 February 201727 February 2017 299,818,66944,972,80050,000,00480,027,20020,000,000- $0.012$0.012$0.012$0.012$0.000 71,641,977539,674600,000960,326240,000(147,859)
Balance 30 June 2017 494,818,673 73,834,118
Share placement ordinary shares on 19 December 2016 and 2 February 2017

The Company issued 44,972,800 and 80,027,200

respectively, in terms of a conditional placement to sophisticated and professional investors at an issue price of 1.2 cents per share.

Share purchase plan

On 12 January 2017, the company issued 50,000,004 ordinary shares under a Share Purchase Plan at an issue price of 1.2 cents per share.

Acquisition of Science Developments Pty Ltd

The company exercised its option to acquire the remaining 50% of Science Developments Pty Ltd. The consideration paid for the exercise of the option amounted to $900,000 and was comprised of $660,000 in cash and the issue of 20,000,000 ordinary shares at an issue price of 1.2 cents per share.

Note 9. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Note 10. Interests in subsidiaries

On 27 February 2017, the consolidated entity acquired the remaining 50% of the ordinary shares of Science Developments Pty Ltd. With the 50% acquisition, the consolidated entity now holds a 100% interest in Science Developments Pty Ltd. The total consideration paid amounted to $900,000 and was comprised of $660,000 in cash and the issue of 20 million fully paid ordinary shares at a deemed issue price of 1.2 cents per share amounting to $240,000. Immediately prior to the purchase, the carrying amount of the existing 50% non-controlling interest in Science Developments Pty Ltd was $254,801. The consolidated entity recognised a decrease in non-controlling interests of $254,801 and a decrease in equity attributable to owners of the parent of $645,199. The effect on the equity attributable to the owners of SciDev Ltd during the year is summarised as follows:

2017$ 2016$
Carrying amount of non-controlling interests acquiredConsideration paid to non-controlling interests 254,801(900,000) --
Excess of consideration paid recognised in the transactions with non-controlling interestsreserve within equity (645,199) -

Note 11. Earnings per share

2017$ 2016$
Loss after income taxNon-controlling interest (597,340)(84,811) (458,130)(22,458)
Loss after income tax attributable to the owners of SciDev Ltd (682,151) (480,588)
Number Number
Weighted average number of ordinary shares used in calculating basic earnings per share 386,472,852 299,818,669
Weighted average number of ordinary shares used in calculating diluted earnings per share 386,472,852 299,818,669
Cents Cents
Basic earnings per shareDiluted earnings per share (0.18)(0.18) (0.16)(0.16)

Options are considered to be potential ordinary shares but were anti-dilutive in nature and therefore the diluted loss per share is the same as the basic loss per share.

Note 12. Share-based payments

On 2 February 2017, the company granted 22,500,000 options to the Lead Manager and Underwriter for services rendered in connection with the placement of shares and the share purchase plan (refer note 8). The options have an exercise price of $0.025, vested on grant date and expire on 28 November 2019. The value of the options granted was $160,828.